Ost-müük Cytokinetics Inc - CYTK CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.17 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Cytokinetics Inc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Eelmine sulgemine* | 38.57 |
Avatud* | 38.13 |
Aastane muutus* | -10.95% |
Päeva ulatus* | 38.13 - 38.84 |
52 nädala ulatus | 32.96-55.80 |
Keskmine maht (10 päeva) | 656.47K |
Keskmine maht (3 kuud) | 20.12M |
Turukapitalisatsioon | 3.69B |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 95.64M |
Tulu | 98.05M |
EPS | -4.58 |
Dividendid (% kasumist) | N/A |
Beeta | 0.79 |
Järgmine tuluaruande kuupäev | Aug 2, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
Jun 2, 2023 | 38.57 | 0.66 | 1.74% | 37.91 | 39.18 | 37.87 |
Jun 1, 2023 | 37.91 | 0.86 | 2.32% | 37.05 | 38.92 | 37.05 |
May 31, 2023 | 37.62 | -0.34 | -0.90% | 37.96 | 38.87 | 37.12 |
May 30, 2023 | 37.93 | 1.02 | 2.76% | 36.91 | 37.98 | 36.80 |
May 26, 2023 | 37.29 | -0.19 | -0.51% | 37.48 | 37.68 | 36.98 |
May 25, 2023 | 37.50 | 0.02 | 0.05% | 37.48 | 37.79 | 36.61 |
May 24, 2023 | 38.11 | -0.62 | -1.60% | 38.73 | 38.73 | 37.70 |
May 23, 2023 | 38.97 | -0.99 | -2.48% | 39.96 | 41.03 | 38.69 |
May 22, 2023 | 40.74 | 2.57 | 6.73% | 38.17 | 40.89 | 37.96 |
May 19, 2023 | 38.94 | 2.09 | 5.67% | 36.85 | 39.01 | 36.77 |
May 18, 2023 | 37.54 | 0.54 | 1.46% | 37.00 | 37.78 | 36.59 |
May 17, 2023 | 37.77 | 1.11 | 3.03% | 36.66 | 37.83 | 36.16 |
May 16, 2023 | 37.19 | -0.78 | -2.05% | 37.97 | 37.97 | 36.47 |
May 15, 2023 | 38.87 | 1.95 | 5.28% | 36.92 | 39.13 | 36.91 |
May 12, 2023 | 37.62 | 0.08 | 0.21% | 37.54 | 37.86 | 36.91 |
May 11, 2023 | 37.79 | 0.01 | 0.03% | 37.78 | 39.46 | 37.62 |
May 10, 2023 | 39.18 | 1.09 | 2.86% | 38.09 | 39.26 | 37.95 |
May 9, 2023 | 38.76 | 1.44 | 3.86% | 37.32 | 38.78 | 37.31 |
May 8, 2023 | 38.36 | -1.06 | -2.69% | 39.42 | 39.52 | 37.82 |
May 5, 2023 | 39.37 | 0.11 | 0.28% | 39.26 | 40.06 | 37.70 |
Cytokinetics Inc Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
Thursday, June 8, 2023 | ||
Kellaaeg (UTC) (UTC) 13:30 | Riik US
| Sündmus Cytokinetics Inc at Jefferies Healthcare Conference Cytokinetics Inc at Jefferies Healthcare ConferenceForecast -Previous - |
Monday, June 12, 2023 | ||
Kellaaeg (UTC) (UTC) 20:20 | Riik US
| Sündmus Cytokinetics Inc at Goldman Sachs Healthcare Conference Cytokinetics Inc at Goldman Sachs Healthcare ConferenceForecast -Previous - |
Wednesday, August 2, 2023 | ||
Kellaaeg (UTC) (UTC) 20:00 | Riik US
| Sündmus Q2 2023 Cytokinetics Inc Earnings Release Q2 2023 Cytokinetics Inc Earnings ReleaseForecast -Previous - |
Wednesday, November 1, 2023 | ||
Kellaaeg (UTC) (UTC) 20:00 | Riik US
| Sündmus Q3 2023 Cytokinetics Inc Earnings Release Q3 2023 Cytokinetics Inc Earnings ReleaseForecast -Previous - |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kogutulu | 94.588 | 70.428 | 55.828 | 26.868 | 31.501 |
Tulu | 94.588 | 70.428 | 55.828 | 26.868 | 31.501 |
Kogu tegevuskulu | 443.729 | 256.741 | 149.771 | 125.735 | 120.417 |
Müük/Üldine/admin kulud, kokku | 177.977 | 96.803 | 52.82 | 39.61 | 31.282 |
Uuringud ja arendus | 240.813 | 159.938 | 96.951 | 86.125 | 89.135 |
Tulud majandustegevusest | -349.141 | -186.313 | -93.943 | -98.867 | -88.916 |
Intressitulud (kulu), muud tulud, neto | -39.814 | -29.001 | -33.347 | -22.825 | -17.373 |
Netotulu enne makse | -388.955 | -215.314 | -127.29 | -121.692 | -106.289 |
Netotulu pärast makse | -388.955 | -215.314 | -127.29 | -121.692 | -106.289 |
Netotulu enne erikulusid | -388.955 | -215.314 | -127.29 | -121.692 | -106.289 |
Netotulu | -388.955 | -215.314 | -127.29 | -121.692 | -106.289 |
Arvestatav tulu, v a erikulud | -388.955 | -215.314 | -127.29 | -121.692 | -106.289 |
Arvestatav tulu, koos erikuludega | -388.955 | -215.314 | -127.29 | -121.692 | -106.289 |
Jaotamisele kuuluv netotulu | -388.955 | -215.314 | -127.29 | -121.692 | -106.289 |
Keskmine jaotamisele kuuluv aktsia kohta | 89.825 | 76.886 | 64.524 | 57.575 | 54.42 |
Jaotatav EPS, v a erakorralised kulud | -4.33014 | -2.80043 | -1.97275 | -2.11363 | -1.95312 |
Jaotamisele kuuluv normaal-EPS | -4.0525 | -2.76401 | -1.97275 | -2.11363 | -1.95312 |
Erakorralised kulud kokku | |||||
Ootamatud kulutused (tulu) | 24.939 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Kogutulu | 4.613 | 1.957 | 2.515 | 88.968 | 1.148 |
Tulu | 4.613 | 1.957 | 2.515 | 88.968 | 1.148 |
Kogu tegevuskulu | 129.086 | 128.987 | 133.202 | 99.842 | 81.698 |
Müük/Üldine/admin kulud, kokku | 49.665 | 53.969 | 48.222 | 42.716 | 33.07 |
Uuringud ja arendus | 79.421 | 75.018 | 62.734 | 57.126 | 45.935 |
Tulud majandustegevusest | -124.473 | -127.03 | -130.687 | -10.874 | -80.55 |
Intressitulud (kulu), muud tulud, neto | -6.816 | -10.35 | -11.623 | -8.946 | -8.895 |
Netotulu enne makse | -131.289 | -137.38 | -142.31 | -19.82 | -89.445 |
Netotulu pärast makse | -131.289 | -137.38 | -142.31 | -19.82 | -89.445 |
Netotulu enne erikulusid | -131.289 | -137.38 | -142.31 | -19.82 | -89.445 |
Netotulu | -131.289 | -137.38 | -142.31 | -19.82 | -89.445 |
Arvestatav tulu, v a erikulud | -131.289 | -137.38 | -142.31 | -19.82 | -89.445 |
Arvestatav tulu, koos erikuludega | -131.289 | -137.38 | -142.31 | -19.82 | -89.445 |
Jaotamisele kuuluv netotulu | -131.289 | -137.38 | -142.31 | -19.82 | -89.445 |
Keskmine jaotamisele kuuluv aktsia kohta | 95.164 | 94.715 | 93.758 | 85.731 | 84.996 |
Jaotatav EPS, v a erakorralised kulud | -1.37961 | -1.45046 | -1.51784 | -0.23119 | -1.05234 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -1.37961 | -1.45046 | -1.28057 | -0.23119 | -1.02066 |
Ootamatud kulutused (tulu) | 0 | 0 | 22.246 | 0 | 2.693 |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Käibevarad kokku | 795.186 | 535.672 | 474.221 | 233.752 | 207.674 |
Raha ja lühiajalised investeeringud | 782.577 | 471.638 | 464.06 | 225.112 | 198.731 |
Raha ja ekvivalendid | 65.582 | 112.666 | 82.985 | 36.433 | 42.256 |
Lühiajalised investeeringud | 716.995 | 358.972 | 381.075 | 188.679 | 156.475 |
Laekumata arved, neto | 0.147 | 51.819 | 4.42 | 5.163 | 6.785 |
Accounts Receivable - Trade, Net | 0.147 | 51.819 | 4.42 | 5.163 | 6.785 |
Prepaid Expenses | 12.462 | 12.215 | 5.741 | 3.477 | 2.158 |
Total Assets | 1014.78 | 841.319 | 533.803 | 289.814 | 211.178 |
Property/Plant/Equipment, Total - Net | 163.19 | 146.409 | 22.628 | 13.412 | 3.204 |
Property/Plant/Equipment, Total - Gross | 180.284 | 162.598 | 47.269 | 37.607 | 27.065 |
Accumulated Depreciation, Total | -17.094 | -16.189 | -24.641 | -24.195 | -23.861 |
Long Term Investments | 46.708 | 152.05 | 36.954 | 42.65 | 0 |
Other Long Term Assets, Total | 9.691 | 7.188 | 0.3 | ||
Total Current Liabilities | 84.617 | 71.86 | 31.199 | 26.023 | 22.194 |
Accounts Payable | 25.611 | 21.087 | 8.05 | 8.16 | 3.764 |
Accrued Expenses | 56.925 | 49.233 | 22.1 | 16.739 | 15.757 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1 | 0.5 | 0 | 2.607 | |
Other Current Liabilities, Total | 1.081 | 1.04 | 1.049 | 1.124 | 0.066 |
Total Liabilities | 1122.68 | 597.456 | 420.42 | 300.751 | 185.244 |
Total Long Term Debt | 610.618 | 143.638 | 135.713 | 129.257 | 39.806 |
Long Term Debt | 609.618 | 142.838 | 135.713 | 129.257 | 39.806 |
Other Liabilities, Total | 427.44 | 381.958 | 253.508 | 145.471 | 123.244 |
Total Equity | -107.9 | 243.863 | 113.383 | -10.937 | 25.934 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.094 | 0.084 | 0.07 | 0.059 | 0.055 |
Additional Paid-In Capital | 1481.59 | 1452.27 | 1105.47 | 853.341 | 768.703 |
Retained Earnings (Accumulated Deficit) | -1585.99 | -1207.62 | -992.306 | -865.016 | -743.324 |
Other Equity, Total | -3.59 | -0.869 | 0.149 | 0.679 | 0.5 |
Total Liabilities & Shareholders’ Equity | 1014.78 | 841.319 | 533.803 | 289.814 | 211.178 |
Total Common Shares Outstanding | 94.834 | 84.7995 | 71.0152 | 59.1721 | 54.7179 |
Capital Lease Obligations | 1 | 0.8 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Käibevarad kokku | 680.629 | 795.186 | 884.275 | 602.25 | 623.526 |
Raha ja lühiajalised investeeringud | 663.962 | 782.577 | 867.664 | 586.026 | 608.974 |
Raha ja ekvivalendid | 101.616 | 65.582 | 106.238 | 93.631 | 115.422 |
Lühiajalised investeeringud | 562.346 | 716.995 | 761.426 | 492.395 | 493.552 |
Laekumata arved, neto | 1.006 | 0.147 | 2.294 | 1.973 | 6.056 |
Accounts Receivable - Trade, Net | 1.006 | 0.147 | 2.294 | 1.973 | 6.056 |
Prepaid Expenses | 15.661 | 12.462 | 14.317 | 14.251 | 8.496 |
Total Assets | 889.815 | 1014.78 | 1075.96 | 771.717 | 856.253 |
Property/Plant/Equipment, Total - Net | 160.661 | 163.19 | 155.378 | 150.747 | 148.386 |
Long Term Investments | 40.406 | 46.708 | 28.544 | 10.668 | 77.083 |
Other Long Term Assets, Total | 8.119 | 9.691 | 7.764 | 8.052 | 7.258 |
Total Current Liabilities | 75.22 | 84.617 | 76.496 | 66.843 | 66.847 |
Accounts Payable | 17.357 | 25.611 | 14.429 | 14.078 | 19.836 |
Accrued Expenses | 49.895 | 56.925 | 56.285 | 51.005 | 43.967 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1 | 1 | 1 | 0.9 | |
Other Current Liabilities, Total | 7.968 | 1.081 | 4.782 | 0.76 | 2.144 |
Total Liabilities | 1118.83 | 1122.68 | 1091.94 | 660.303 | 739.992 |
Total Long Term Debt | 610.623 | 610.618 | 609.73 | 198.418 | 197.076 |
Long Term Debt | 610.623 | 609.618 | 608.53 | 197.018 | 195.676 |
Other Liabilities, Total | 432.992 | 427.44 | 405.712 | 395.042 | 476.069 |
Total Equity | -229.02 | -107.9 | -15.977 | 111.414 | 116.261 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.094 | 0.094 | 0.093 | 0.085 | 0.085 |
Additional Paid-In Capital | 1489.81 | 1481.59 | 1438.1 | 1422.13 | 1406.25 |
Retained Earnings (Accumulated Deficit) | -1717.28 | -1585.99 | -1448.61 | -1306.3 | -1286.48 |
Other Equity, Total | -1.645 | -3.59 | -5.559 | -4.494 | -3.589 |
Total Liabilities & Shareholders’ Equity | 889.815 | 1014.78 | 1075.96 | 771.717 | 856.253 |
Total Common Shares Outstanding | 95.6093 | 94.834 | 94.578 | 85.9152 | 85.577 |
Capital Lease Obligations | 1 | 1.2 | 1.4 | 1.4 |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Netotulu/algväärtus | -388.955 | -215.314 | -127.29 | -121.692 | -106.289 |
Raha majandustegevusest | -299.516 | -142.522 | 8.943 | -90.907 | -101.215 |
Raha majandustegevusest | 5.814 | 2.276 | 1.831 | 1.293 | 1.239 |
Mittelikviidsed varad | 105.744 | 54.699 | 45.285 | 29.828 | 26.771 |
Cash Taxes Paid | 0.001 | ||||
Makstud intressid | 15.165 | 9.175 | 9.62 | 4.059 | 2.877 |
Muutused tööjõus | -22.119 | 15.817 | 89.117 | -0.336 | -22.936 |
Tulu investeeringutelt | -262.134 | -147.777 | -196.515 | -74.707 | 5.133 |
Kapitalikulutused | -11.335 | -48.872 | -11.052 | -2.619 | -0.889 |
Muud rahavood investeeringutelt, kokku | -250.799 | -98.905 | -185.463 | -72.088 | 6.022 |
Rahavood investeeringutelt | 516.166 | 319.98 | 234.124 | 159.791 | 13.132 |
Rahavoogudesse investeerimine | 31.924 | 7.931 | 7.507 | -11.993 | 3.234 |
Aktsiate emiteerimine (tagasiost), neto | 0 | 312.049 | 226.617 | 36.214 | 0 |
Laenu väljastamine (kustutamine), neto | 484.242 | 0 | 0 | 135.57 | 9.898 |
Rahaline kogumuutus | -45.484 | 29.681 | 46.552 | -5.823 | -82.95 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -131.289 | -388.955 | -251.575 | -109.265 | -89.445 |
Cash From Operating Activities | -122.286 | -299.516 | -201.326 | -117.286 | -26.811 |
Cash From Operating Activities | 1.848 | 5.814 | 4.156 | 2.748 | 1.341 |
Non-Cash Items | 25.392 | 105.744 | 86.135 | 41.684 | 20.574 |
Changes in Working Capital | -18.237 | -22.119 | -40.042 | -52.453 | 40.719 |
Cash From Investing Activities | 165.497 | -262.134 | -291.383 | 0.989 | -64.279 |
Capital Expenditures | -0.402 | -11.335 | -8.13 | -1.799 | -0.942 |
Other Investing Cash Flow Items, Total | 165.899 | -250.799 | -283.253 | 2.788 | -63.337 |
Cash From Financing Activities | -7.177 | 516.166 | 486.281 | 97.262 | 93.846 |
Financing Cash Flow Items | -6.97 | 31.924 | 1.934 | -4.253 | -7.936 |
Net Change in Cash | 36.034 | -45.484 | -6.428 | -19.035 | 2.756 |
Issuance (Retirement) of Stock, Net | 0 | 0 | |||
Issuance (Retirement) of Debt, Net | -0.207 | 484.242 | 484.347 | 101.515 | 101.782 |
Cash Interest Paid | 0.04 | 15.165 | 5.555 | 5.474 | 2.714 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 14.3062 | 13682547 | -302816 | 2023-03-31 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 11.571 | 11066582 | -514289 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 10.6277 | 10164417 | 110238 | 2023-03-31 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 7.8697 | 7526617 | 983893 | 2023-03-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.9706 | 4753900 | -291014 | 2023-03-31 | LOW |
American Century Investment Management, Inc. | Investment Advisor/Hedge Fund | 2.8008 | 2678698 | 1496881 | 2023-03-31 | LOW |
Polar Capital LLP | Investment Advisor/Hedge Fund | 2.7307 | 2611692 | -113085 | 2023-03-31 | LOW |
RTW Investments L.P. | Investment Advisor/Hedge Fund | 2.6915 | 2574198 | 0 | 2023-03-31 | LOW |
PFM Health Sciences, LP | Hedge Fund | 2.5089 | 2399545 | 0 | 2023-03-31 | MED |
Lord, Abbett & Co. LLC | Investment Advisor | 2.4124 | 2307269 | -617042 | 2023-03-31 | MED |
Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 2.3739 | 2270391 | 5079 | 2023-03-31 | LOW |
Boxer Capital, L.L.C. | Hedge Fund | 2.1957 | 2100000 | 0 | 2023-03-31 | LOW |
Fidelity Institutional Asset Management | Investment Advisor | 1.8802 | 1798230 | 19143 | 2023-03-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.8138 | 1734696 | 76846 | 2023-03-31 | LOW |
Janus Henderson Investors | Investment Advisor/Hedge Fund | 1.6454 | 1573644 | 1399714 | 2023-03-31 | LOW |
T. Rowe Price Investment Management, Inc. | Investment Advisor | 1.5873 | 1518062 | 1054416 | 2023-03-31 | MED |
Invus Public Equities Advisors, LLC | Investment Advisor | 1.4293 | 1367023 | 367023 | 2023-03-31 | LOW |
Logos Global Management LLC | Investment Advisor | 1.307 | 1250000 | -250000 | 2023-03-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 1.1784 | 1127037 | 62308 | 2023-03-31 | LOW |
Invesco Advisers, Inc. | Investment Advisor | 1.1652 | 1114391 | 63459 | 2023-03-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group535K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$113M+
Igakuine investeerimise maht
$64M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cytokinetics Inc Company profile
Ettevõttest Cytokinetics Inc
Cytokinetics, Incorporated on hilisstaadiumis biofarmatseutiline ettevõte, mis keskendub lihaste aktiveerijate ja lihasinhibiitorite avastamisele, arendamisele ja turustamisele kui potentsiaalsetele ravimeetoditele invaliidistavate haiguste puhul. Ettevõte töötab välja väikemolekulaarseid ravimikandidaate, mis on spetsiaalselt kavandatud mõjutama lihaste funktsiooni ja kontraktiilsust. Ettevõte viib praegu läbi METEORIC-HF, mis on omecamtiv-mekarbiili teine III faasi kliiniline uuring. Ettevõte arendab ka südamemüosiini inhibiitorit aficamtenit, mis on mõeldud HCM potentsiaalseks raviks. Ettevõte uurib ja arendab ka uudseid ravimeetodeid, mis on seotud lihaste funktsiooni häiretega, mis ei ole seotud lihaste kokkutõmbuvusega. Ettevõtte juhtivad kliinilises arenduses olevad ravimikandidaadid on omecamtiv mecarbil, südame müosiini aktivaator; CK-136, südame troponiini aktivaator; reldesemtiv, kiire skeletilihase troponiini aktivaator (FSTA) ja CK-3773274 (CK-274), südame müosiini inhibiitor.
Industry: | Bio Therapeutic Drugs |
.
280 East Grand Avenue
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 535,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com